Facilitators and Barriers to Cancer Treatment Among Texas Residents

February 26, 2026 updated by: M.D. Anderson Cancer Center
This trial uses semi-structured interviews and focus groups to determine facilitators and barriers of receiving timely cancer treatment among multiple cancers, across multiple insurance types, throughout Texas

Study Overview

Status

Not yet recruiting

Conditions

Intervention / Treatment

Detailed Description

Primary Objectives:

Aim 1: To comprehensively assess barriers to and facilitators of receiving timely cancer treatment, via in-depth telephone interviews among a purposive sample of Texas patients with Stage I-IV breast, colorectal, lung, and prostate cancer and diverse backgrounds.

Aim 2: To generate consensus on barriers and facilitators, as well as their relative importance, via focus groups, among carefully selected Texas patients with Stage I-IV breast, colorectal, lung and prostate cancer and diverse backgrounds,

Study Type

Interventional

Enrollment (Estimated)

120

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

  • United States
    • Texas
      • Houston, Texas, United States, 77030
        • The University of Texas M. D. Anderson Cancer Center
        • Contact:
        • Principal Investigator:
          • John Lin, MD

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

Aims 1 and 2

In order to be eligible to participate in this study, an individual must meet all of the following criteria:

  • Verbal consent will be obtained
  • Stated willingness to comply with all study procedures and lifestyle considerations and availability for the duration of the study
  • Males and females; Age ≥ 18 years old
  • Documented diagnosis of breast, colorectal, lung, and prostate cancer patients, stage I-IV
  • Either English or Spanish-speaking

Exclusion Criteria:

Aims 1 and 2

An individual who meets any of the following criteria will be excluded from participation in this study:

  • Patients who are cognitively impaired
  • Pregnant women

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Health Services Research
  • Allocation: Non-Randomized
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Semi-structured Interview
Participants will be recruited through the Texas Cancer Registry (TCR).
Other: Focus Groups
45 to 60 minutes video conference
Experimental: Online Focus Group
Participants will be recruited through the Texas Cancer Registry (TCR).
Other: Interviews
A 30 to 45-minute in-depth semi-structured interview by phone will be administer, following a semi-structured interview guide.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
1. Safety and Adverse Events (AEs)
Time Frame: Through study completion; an average of 1 year
Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version (v) 5.0
Through study completion; an average of 1 year

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

M.D. Anderson Cancer Center

Investigators

  • Principal Investigator: John Lin, MD, M.D. Anderson Cancer Center

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Helpful Links

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

January 31, 2026

Primary Completion (Estimated)

December 31, 2026

Study Completion (Estimated)

December 31, 2028

Study Registration Dates

First Submitted

July 29, 2025

First Submitted That Met QC Criteria

July 29, 2025

First Posted (Actual)

August 5, 2025

Study Record Updates

Last Update Posted (Actual)

March 2, 2026

Last Update Submitted That Met QC Criteria

February 26, 2026

Last Verified

February 1, 2026

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 2025-0697
  • NCI-2025-05584 (Other Identifier: NCI-CTRP Clinical Trials Registry)

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Cancer

Clinical Trials on Focus Groups

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Türkiye

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe